2639 Results

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Younes
    Younes
  7. Matasar
    Matasar
  8. Moskowitz
    Moskowitz
  9. Yahalom
    Yahalom
  10. Portlock
    Portlock

Groups

  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)
  7. Executive Committee, Center for Hematologic Malignancies (389)
  8. Epidemiology and Biostatistics (363)
  9. GSK Faculty (356)
  10. Department of Pathology and Laboratory Medicine (300)
  1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Autologous hematopoietic cell transplantation for HIV-related lymphoma: Results of the BMT CTN 0803/AMC 071 trial
    Journal Article

    Alvarnas, J. C.; Le Rademacher, J.; Wang, Y.; Little, R. F.; Akpek, G.; Ayala, E.; Devine, S.; Baiocchi, R.; Lozanski, G.; Kaplan, L.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Patterns of idelalisib treatment-emergent lymphocytosis in patients with CLL or SLL
    Meeting Abstract

    Ghia, P.; Cheson, B. D.; Furman, R. R.; Hallek, M.; Hillmen, P.; O'Brien, S. M.; Sharman, J. P.; Dubowy, R. L.; Velasco, B.; Waldapfel, C. C.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Phase 1 final results and phase 2a dose selection for cerdulatinib (Prt062070) a dual SYK/JAK inhibitor in patients with relapsed/refractory B cell malignancies
    Meeting Abstract

    Hamlin, P.; Flinn, I.; Wagner-Johnston, N.; Burger, J.; Michelson, G.; Pandey, A.; Birrell, M.; Coffey, G.; Leeds, J.; Sabalvaro-Torres, A.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Idelalisib plus an anti-Cd20 antibody in patients with chronic lymphocytic leukemia (CLL) who are HBV core antibody positive: Similar patterns of liver test abnormalities
    Meeting Abstract

    Robak, T.; Zelenetz, A. D.; Mato, A.; Jones, J. A.; Pagel, J. M.; Barrientos, J. C.; Brown, J. R.; Montillo, M.; Dubowy, R.; Xing, G.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Idelalisib in combination with bendamustine/rituximab improves overall survival in patients with relapsed/refractory CLL: Interim results of a phase 3 randomized double-blind placebo-controlled study
    Meeting Abstract

    Hillmen, P.; Ferra, C.; Garcia-Marco, J.; Jacob, A.; Jurczak, W.; Lamanna, N.; MacDonald, D.; Marlton, P.; Mayer, J.; Morchauser, F.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Checkmate 205: A phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin
    Meeting Abstract

    Engert, A.; Santoro, A.; Shipp, M.; Zinzani, P. L.; Timmerman, J.; Ansell, S.; Armand, P.; Fanale, M.; Ratanatharathorn, V.; Kuruvilla, J.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Phase 1 trial of CUDC-907, a novel, oral dual inhibitor of HDAC and Pi3k: Updated assessment of patients with relapsed or refractory diffuse large B-cell lymphoma, including double expressor lymphoma
    Meeting Abstract

    Younes, A.; Berdeja, J.; Patel, M.; Kelly, K.; Flinn, I.; Gerecitano, J.; Neelapu, S.; Copeland, A.; Wang, J.; Gong, L.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Management of transaminase elevations associated with idelalisib
    Meeting Abstract

    Ghia, P.; Coutre, S.; Flinn, I. W.; Gopal, A. K.; O'Brien, S. M.; Salles, G. A.; Newcomb, T.; Waldapfel, C. C.; Ye, W.; Zelenetz, A. D.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • A phase IB study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma
    Meeting Abstract

    Palomba, M. L.; Till, B. G.; Park, S. I.; Morschhauser, F.; Cartron, G.; Marks, R.; Penuel, E.; Chitra, S.; Byon, J. C. H.; Popplewell, L.
    Haematologica (2016)

    Fulltext@MSK | Save
  • An evaluation of the CLL-IPI score and comprehensive prognostic factor analysis in patients with R/R CLL in idelalisib phase 3 randomized studies
    Meeting Abstract

    Soumerai, J. D.; Barrientos, J. C.; Hallek, M.; Kipps, T. J.; Jones, J. A.; Xing, G.; Yao, N. S.; Ysebaert, L.; Stilgenbauer, S.; Zelenetz, A. D.
    Haematologica (2016)

    Fulltext@MSK | Save